BofA analyst Jason Zemansky initiated coverage of Cytokinetics with a Neutral rating and $49 price target. The analyst is cautious on the opportunity for the company’s next generation myosin inhibitor aficamten. The firm believes aficamten is likely to face "underappreciated" operational and access headwinds that have also slowed Bristol-Myers’ Camzyos.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on CYTK:
- Cytokinetics to Announce Fourth Quarter Results on March 1, 2023
- Cytokinetics management to meet with Cantor Fitzgerald
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Cytokinetics Announces Recipients of Its Fifth Annual Communications Grant Program
- Truist healthcare analysts to hold an analyst/industry conference call